Bhavana Patel1, David J Irwin2, Daniel Kaufer3, Bradley F Boeve4, Angela Taylor5,6, Melissa J Armstrong1. 1. Department of Neurology, McKnight Brain Institute, University of Florida College of Medicine, Gainesville. 2. Department of Neurology, University of Pennsylvania, Philadelphia, PA. 3. Departments of Neurology and Psychiatry, University of North Carolina, Chapel Hill, NC. 4. Department of Neurology and Center for Sleep Medicine, Mayo Clinic, Rochester, MN. 5. Department of Neurology, Comprehensive Center for Brain Health, University of Miami Miller School of Medicine, Miami, FL. 6. Lewy Body Dementia Association, Lilburn, GA.
Abstract
BACKGROUND: Dementia with Lewy bodies (DLB) is one of the most common degenerative dementias. Clinical trials for individuals with DLB are increasing. We aimed to identify commonly used outcome measures for trials in DLB. METHODS: A pragmatic literature search of PubMed and clinicaltrials.gov identified interventional studies including populations with DLB. Studies were included if they enrolled participants with DLB and met the National Institutes of Health criteria for a clinical trial. Data were collected using standardized forms. Outcome measures were categorized according to core and supportive features of DLB. RESULTS: After de-duplication, 58 trials were identified. The most common cognitive outcome measures were the Mini Mental State Examination (n=24) and Cognitive Drug Research computerized Assessment System (n=5). The Clinician's Assessment of Fluctuations was the most commonly used measure for fluctuations (n=4). Over half of studies used the Neuropsychiatric Inventory to assess behavioral symptoms (n=31). The Unified Parkinson's Disease Rating Scale was frequently used for motor assessment (n=23). CONCLUSIONS AND RELEVANCE: Clinical trial outcomes used in DLB are rarely validated in this population and some lack face validity. There is a need to validate existing scales in DLB and develop DLB-specific outcome measures.
BACKGROUND: Dementia with Lewy bodies (DLB) is one of the most common degenerative dementias. Clinical trials for individuals with DLB are increasing. We aimed to identify commonly used outcome measures for trials in DLB. METHODS: A pragmatic literature search of PubMed and clinicaltrials.gov identified interventional studies including populations with DLB. Studies were included if they enrolled participants with DLB and met the National Institutes of Health criteria for a clinical trial. Data were collected using standardized forms. Outcome measures were categorized according to core and supportive features of DLB. RESULTS: After de-duplication, 58 trials were identified. The most common cognitive outcome measures were the Mini Mental State Examination (n=24) and Cognitive Drug Research computerized Assessment System (n=5). The Clinician's Assessment of Fluctuations was the most commonly used measure for fluctuations (n=4). Over half of studies used the Neuropsychiatric Inventory to assess behavioral symptoms (n=31). The Unified Parkinson's Disease Rating Scale was frequently used for motor assessment (n=23). CONCLUSIONS AND RELEVANCE: Clinical trial outcomes used in DLB are rarely validated in this population and some lack face validity. There is a need to validate existing scales in DLB and develop DLB-specific outcome measures.
Authors: I G McKeith; J B Grace; Z Walker; E J Byrne; D Wilkinson; T Stevens; E K Perry Journal: Int J Geriatr Psychiatry Date: 2000-05 Impact factor: 3.485
Authors: Hubert H Fernandez; Dag Aarsland; Gilles Fénelon; Joseph H Friedman; Laura Marsh; Alexander I Tröster; Werner Poewe; Olivier Rascol; Cristina Sampaio; Glenn T Stebbins; Christopher G Goetz Journal: Mov Disord Date: 2008-03-15 Impact factor: 10.338
Authors: Ian G McKeith; Bradley F Boeve; Dennis W Dickson; Glenda Halliday; John-Paul Taylor; Daniel Weintraub; Dag Aarsland; James Galvin; Johannes Attems; Clive G Ballard; Ashley Bayston; Thomas G Beach; Frédéric Blanc; Nicolaas Bohnen; Laura Bonanni; Jose Bras; Patrik Brundin; David Burn; Alice Chen-Plotkin; John E Duda; Omar El-Agnaf; Howard Feldman; Tanis J Ferman; Dominic Ffytche; Hiroshige Fujishiro; Douglas Galasko; Jennifer G Goldman; Stephen N Gomperts; Neill R Graff-Radford; Lawrence S Honig; Alex Iranzo; Kejal Kantarci; Daniel Kaufer; Walter Kukull; Virginia M Y Lee; James B Leverenz; Simon Lewis; Carol Lippa; Angela Lunde; Mario Masellis; Eliezer Masliah; Pamela McLean; Brit Mollenhauer; Thomas J Montine; Emilio Moreno; Etsuro Mori; Melissa Murray; John T O'Brien; Sotoshi Orimo; Ronald B Postuma; Shankar Ramaswamy; Owen A Ross; David P Salmon; Andrew Singleton; Angela Taylor; Alan Thomas; Pietro Tiraboschi; Jon B Toledo; John Q Trojanowski; Debby Tsuang; Zuzana Walker; Masahito Yamada; Kenji Kosaka Journal: Neurology Date: 2017-06-07 Impact factor: 9.910
Authors: Bradley F Boeve; Dennis W Dickson; John E Duda; Tanis J Ferman; Douglas R Galasko; James E Galvin; Jennifer G Goldman; John H Growdon; Howard I Hurtig; Daniel I Kaufer; Kejal Kantarci; James B Leverenz; Carol F Lippa; Oscar L Lopez; Ian G McKeith; Andrew B Singleton; Angela Taylor; Debby Tsuang; Daniel Weintraub; Cyrus P Zabetian Journal: Mov Disord Date: 2016-08-05 Impact factor: 10.338
Authors: Matej Skorvanek; Jennifer G Goldman; Marjan Jahanshahi; Connie Marras; Irena Rektorova; Ben Schmand; Erik van Duijn; Christopher G Goetz; Daniel Weintraub; Glenn T Stebbins; Pablo Martinez-Martin Journal: Mov Disord Date: 2017-11-23 Impact factor: 10.338
Authors: Federico Rodriguez-Porcel; Kathryn A Wyman-Chick; Carla Abdelnour Ruiz; Jon B Toledo; Daniel Ferreira; Prabitha Urwyler; Rimona S Weil; Joseph Kane; Andrea Pilotto; Arvid Rongve; Bradley Boeve; John-Paul Taylor; Ian McKeith; Dag Aarsland; Simon J G Lewis Journal: Transl Neurodegener Date: 2022-05-02 Impact factor: 9.883
Authors: Ying Jiang; John J Alam; Stephen N Gomperts; Paul Maruff; Afina W Lemstra; Ursula A Germann; Philip H Stavrides; Sandipkumar Darji; Sandeep Malampati; James Peddy; Cynthia Bleiwas; Monika Pawlik; Anna Pensalfini; Dun-Sheng Yang; Shivakumar Subbanna; Balapal S Basavarajappa; John F Smiley; Amanda Gardner; Kelly Blackburn; Hui-May Chu; Niels D Prins; Charlotte E Teunissen; John E Harrison; Philip Scheltens; Ralph A Nixon Journal: Nat Commun Date: 2022-09-21 Impact factor: 17.694